BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Canavan Disease

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced...

Related Keywords

United States ,University Of Massachusetts Medical School ,Massachusetts ,Adam Shaywitz ,Florian Eichler ,Dominicj Gessler ,Guangping Gao ,Katherine Yau ,Eric David ,Linkedin ,Twitter ,Nasdaq ,Bridgebio Pharma Inc ,Li Weibo Institute For Rare Diseases Research ,European Union ,Drug Administration ,Leukodystrophy Service ,Exchange Commission ,European Medicines Agency ,Securities Exchange ,Bio Pharma Inc ,Pharma Inc ,Horae Gene Therapy Center ,Bridgebio Gene ,Massachusetts General Hospital ,Massachusetts Medical ,Rare Diseases Research ,Viral Vector Core ,Fast Track Designation ,Rare Pediatric Drug Designation ,Orphan Drug Designation ,European Medicines ,Bridgebio Pharma ,Bio Pharma ,Securities Act ,Securities Exchange Act ,Exchange Act ,Risk Factors ,Annual Report ,Bio Media Contact ,Bio Investor Contact ,Bridgebio ,